MFAP2 is identified as a potential prognostic biomarker for colorectal cancer (CRC). (IMAGE)
Caption
(A, B) The mRNA and protein expression of MFAP2 was significantly higher in colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ), validated through various data sources, including TCGA (A) and CPTAC (B).
(C, D) MFAP2 was significantly up-regulated in CRC patients and related to tumor progression, validated by GEPIA data.
(E) Patients with tumor recurrence were accompanied by significantly higher expression of MFAP2.
(F) CRC patients with high MFAP2 expression had significantly lower disease-free survival (DFS).
(G–J) Immunohistochemical results showed that MFAP2 was significantly overexpressed in CRC tissues, and MFAP2 expression was higher in patients with larger tumor sizes or older age.
Credit
Zhicheng He, Yuanzhi Chen, Shuting Yang, Cheng Chen, Yingying He, Shubai Liu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND